Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data
In this national dataset, adjuvant trastuzumab was associated with improvements in survival, with an OS effect size similar to RCT evidence. The effect size was not found to vary by patient age or fitness. Chronological age and fitness alone should not be barriers to receipt of effective adjuvant targeted treatment.
Authors
- David Dodwell (ORCID: https://orcid.org/0000-0001-8787-4904)
- Melissa Gannon (ORCID: https://orcid.org/0000-0002-9163-0571)
- David Cromwell (ORCID: https://orcid.org/0000-0002-6516-8125)
- Min Hae Park (ORCID: https://orcid.org/0000-0002-2563-4910)
- Francisco J. Medina (ORCID: https://orcid.org/0000-0002-3657-1716)
- Karen Clements (ORCID: https://orcid.org/0000-0003-0113-4409)
- Kieran Horgan (ORCID: https://orcid.org/0000-0003-4173-1777)
- Katie Miller (ORCID: https://orcid.org/0000-0001-8079-9980)
Institutions
- Royal College of Surgeons of England (GB)
- St James's University Hospital (GB)
- University of Oxford (GB)
- London School of Hygiene & Tropical Medicine (GB)
- National Cancer Registration Service (GB)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1016/j.ejca.2024.114309
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Heart of England NHS Foundation Trust
- Llywodraeth Cymru
- Cancer Research UK